Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF

DBV Technologies
Posted on: 13 Jul 18
AMF REGULATED INFORMATION
Montrouge, France, July 13, 2018

Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year Report on its liquidity contract with Natixis. Due to the partnership between Natixis and Oddo BHF, the liquidity contract on DBV Technologies shares originally entrusted to Natixis, was transferred to Oddo BHF as of July 2, 2018.

At the close of the liquidity agreement, the following assets appeared on the liquidity account: 24,313 DBV Technologies shares and € 682,454.94. As of December 29, 2017, the following assets appeared on the liquidity account: 4,939 DBV Technologies shares and € 1,332,828.26. Per the contract dated June 19, 2018 and for a period of one year, which is tacitly renewable, Oddo BHF and Natixis will implement DBV Technologies liquidity and market surveillance contract on ordinary shares, in accordance with the AMAFI code of Ethics from March 8, 2011 approved by AMF on March 21, 2011.

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company's ordinary shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

DBV Media Contact
Raul Damas
Partner, Brunswick Group
+1-212-333-3810
DBV@brunswickgroup.com

PDF version


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DBV Technologies via GlobeNewswire
HUG#2205018
GlobeNewswire
globenewswire.com

Last updated on: 16/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.